Here are three things to know
1. Mylan’s glatiramer acetate injection is intended to treat patients with relapsing forms of MS.
2. The FDA approved two forms of the generic drug — a larger dose injected three times a week and a smaller dose injected daily.
3. Mylan will launch a patient support service program in conjunction with the generic drug, which will include an interactive mobile app, in-home injection training and co-pay assistance for eligible patients, among other features.
More articles on supply chain:
FDA commissioner: High drug prices are a ‘public health concern the FDA should address’
Judge ruling allows drug ‘price gouging’ law to take effect in Maryland
Rite Aid names former Walgreens executive as president, COO
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
